Evidence map›Paper›PMID 39696656›Full record

ArticleEuropean journal of medical research2024

Involvement of CXCL12/CXCR4 in CB2 receptor agonist-attenuated morphine tolerance in Walker 256 tumor-bearing rats with cancer pain.

Dandan Liu, Mingyue Zhang, Xiaohai Xu, Xuelai Zhong, Chao Ma, Xiaoyu Zheng, Xiaohong Wu, Guonian Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dandan LiuDepartment of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Mingyue ZhangDepartment of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Xiaohai XuDepartment of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Xuelai ZhongDepartment of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, China.
Chao MaDepartment of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
Xiaoyu ZhengDepartment of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Xiaohong WuDepartment of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150081, China. wuxiaohong@hrbmu.edu.cn.
Guonian WangDepartment of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150081, China. wangguonian609cn@aliyun.com.

Funding

Harbin Medical University 2022-KYYWF-0287Harbin Medical University YJSKYCX2019-96HYDNational Natural Science Foundation of China grant nos. 8177051154 and 82172192
6 · The paper itself

Abstract

While low-dose cannabinoid 2 (CB2) receptor agonists attenuate morphine tolerance in cancer pain models, chemokine ligand 12 (CXCL12)/chemokine receptor 4 (CXCR4) expression induces morphine tolerance. Whether CB2 receptor agonists attenuate morphine tolerance by modulating CXCL12/CXCR4 signaling or whether CXCL12/CXCR4 signaling affects the mu opioid receptor (MOR) in the development of morphine tolerance in cancer pain remains unclear. In this study, we investigated the attenuation of morphine tolerance by a non-analgesic dose of the CB2 receptor agonist AM1241, focusing specifically on the modulation of CXCL12/CXCR4 signaling and its effect on the MOR. Rats received intrathecal Walker 256 tumor cell implantations and were treated with morphine combined with the intrathecal injection of AM1241 or the CB2 receptor antagonists AM630 and AM1241, or a CXCL12-neutralizing antibody, exogenous CXCL12, or the CXCR4 antagonist AMD3100. Our results show that CXCL12 and CXCR4 levels increased significantly in morphine-tolerant rats and were reduced by AM1241 pretreatment, which was reversed by AM630. CXCL12/CXCR4 expression accelerated the development of morphine tolerance and downregulated MOR expression. CXCR4 colocalized with MOR and CB2. Therefore, a non-analgesic dose of AM1241 attenuated morphine tolerance via CXCL12/CXCR4 signaling, whereas CXCL12/CXCR4 signaling participated in the development of morphine tolerance, potentially by modulating MOR expression in Walker 256 tumor-bearing rats.

Indexed as

Cancer PainCarcinoma 256, WalkerChemokine CXCL12Drug ToleranceMorphineReceptor, Cannabinoid, CB2Receptors, CXCR4Analgesics, OpioidAnimalsCannabinoidsMaleRatsRats, WistarReceptors, Opioid, muSignal TransductionAM 1241Analgesics, OpioidCannabinoidsChemokine CXCL12CXCL12 protein, ratCxcr4 protein, ratMorphineReceptor, Cannabinoid, CB2Receptors, CXCR4Receptors, Opioid, muCancer painCannabinoid 2Chemokine ligand 12/chemokine receptor 4Morphine toleranceMu opioid receptor

Identifiers

PMID39696656
PMCPMC11656961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.